Biomarkers of liver injury are of increasing importance in the development of new drugs. The liver plays a central role in metabolizing and clearing chemicals and is susceptible to the toxicity from these agents. Many drugs have been implicated in causing liver injury and it is the most common reason for a drug to be withdrawn from the market. Hepatotoxicity and drug-induced liver injury also account for a substantial number of compound failures, highlighting the need for drug screening assays, such as stem cell-derived hepatocyte-like cells, that are capable of detecting toxicity early in the drug development process. Chemicals often cause subclinical injury to the liver, which manifests only as abnormal liver enzyme tests.

 

MSD provides solutions to support and simplify your liver injury research needs. We offer assays to measure biomarkers such as αGST and arginase-1.